PURPOSE: Bioengineered dermo-epidermal skin analogs containing melanocytes represent a promising approach to cover large skin defects including restoration of the patient's own skin color. So far, little is known about the development of blood and lymphatic vessels in pigmented skin analogs after transplantation. In this experimental study, we analyzed the advancement and differences of host blood and lymphatic vessel ingrowth into light- and dark-pigmented human tissue-engineered skin analogs in a rat model. METHODS: Keratinocytes, melanocytes, and fibroblasts from light- and dark-pigmented skin biopsies were isolated, cultured, and expanded. For each donor, melanocytes and keratinocytes were seeded in ratios of 1:1, 1:5, and 1:10 onto fibroblast-containing collagen gels. The skin analogs were subsequently transplanted onto full-thickness wounds of immuno-incompetent rats and quantitatively analyzed for vascular and lymphatic vessel density after 8 and 15 weeks. RESULTS: The skin analogs revealed a significant difference in vascularization patterns between light- and dark-pigmented constructs after 8 weeks, with a higher amount of blood vessels in light compared to dark skin. In contrast, no obvious difference could be detected within the light- and dark-pigmented group when varying melanocyte/keratinocyte ratios were used. However, after 15 weeks, the aforementioned difference in blood vessel density between light and dark constructs could no longer be detected. Regarding lymphatic vessels, light and dark analogs showed similar vessel density after 8 and 15 weeks, while there were generally less lymphatic than blood vessels. CONCLUSION: These data suggest that, at least during early skin maturation, keratinocytes, melanocytes, and fibroblasts from different skin color types used to construct pigmented dermo-epidermal skin analogs have distinct influences on the host tissue after transplantation. We speculate that different VEGF expression patterns might be involved in this disparate revascularization pattern observed.
PURPOSE: Bioengineered dermo-epidermal skin analogs containing melanocytes represent a promising approach to cover large skin defects including restoration of the patient's own skin color. So far, little is known about the development of blood and lymphatic vessels in pigmented skin analogs after transplantation. In this experimental study, we analyzed the advancement and differences of host blood and lymphatic vessel ingrowth into light- and dark-pigmented human tissue-engineered skin analogs in a rat model. METHODS: Keratinocytes, melanocytes, and fibroblasts from light- and dark-pigmented skin biopsies were isolated, cultured, and expanded. For each donor, melanocytes and keratinocytes were seeded in ratios of 1:1, 1:5, and 1:10 onto fibroblast-containing collagen gels. The skin analogs were subsequently transplanted onto full-thickness wounds of immuno-incompetent rats and quantitatively analyzed for vascular and lymphatic vessel density after 8 and 15 weeks. RESULTS: The skin analogs revealed a significant difference in vascularization patterns between light- and dark-pigmented constructs after 8 weeks, with a higher amount of blood vessels in light compared to dark skin. In contrast, no obvious difference could be detected within the light- and dark-pigmented group when varying melanocyte/keratinocyte ratios were used. However, after 15 weeks, the aforementioned difference in blood vessel density between light and dark constructs could no longer be detected. Regarding lymphatic vessels, light and dark analogs showed similar vessel density after 8 and 15 weeks, while there were generally less lymphatic than blood vessels. CONCLUSION: These data suggest that, at least during early skin maturation, keratinocytes, melanocytes, and fibroblasts from different skin color types used to construct pigmented dermo-epidermal skin analogs have distinct influences on the host tissue after transplantation. We speculate that different VEGF expression patterns might be involved in this disparate revascularization pattern observed.
Authors: Sophie Böttcher-Haberzeth; Thomas Biedermann; Clemens Schiestl; Fabienne Hartmann-Fritsch; Jörg Schneider; Ernst Reichmann; Martin Meuli Journal: Pediatr Surg Int Date: 2012-02 Impact factor: 1.827
Authors: Thomas Biedermann; Sophie Böttcher-Haberzeth; Agnieszka S Klar; Luca Pontiggia; Clemens Schiestl; Claudia Meuli-Simmen; Ernst Reichmann; Martin Meuli Journal: Pediatr Surg Int Date: 2013-01 Impact factor: 1.827
Authors: Sophie Böttcher-Haberzeth; Thomas Biedermann; Luca Pontiggia; Erik Braziulis; Clemens Schiestl; Bart Hendriks; Ossia M Eichhoff; Daniel S Widmer; Claudia Meuli-Simmen; Martin Meuli; Ernst Reichmann Journal: J Invest Dermatol Date: 2012-09-13 Impact factor: 8.551
Authors: Thomas Biedermann; Luca Pontiggia; Sophie Böttcher-Haberzeth; Sasha Tharakan; Erik Braziulis; Clemens Schiestl; Martin Meuli; Ernst Reichmann Journal: J Invest Dermatol Date: 2010-04-08 Impact factor: 8.551
Authors: Luca Pontiggia; Thomas Biedermann; Martin Meuli; Daniel Widmer; Sophie Böttcher-Haberzeth; Clemens Schiestl; Jörg Schneider; Erik Braziulis; Irene Montaño; Claudia Meuli-Simmen; Ernst Reichmann Journal: J Invest Dermatol Date: 2008-08-21 Impact factor: 8.551
Authors: Thomas Biedermann; Sophie Böttcher-Haberzeth; Agnieszka S Klar; Daniel S Widmer; Luca Pontiggia; Andreas D Weber; Daniel M Weber; Clemens Schiestl; Martin Meuli; Ernst Reichmann Journal: Tissue Eng Part A Date: 2015-01-07 Impact factor: 3.845
Authors: Agnes S Klar; Katarzyna Michalak-Mićka; Thomas Biedermann; Claudia Simmen-Meuli; Ernst Reichmann; Martin Meuli Journal: Pediatr Surg Int Date: 2017-11-09 Impact factor: 1.827
Authors: Agnes S Klar; Thomas Biedermann; Claudia Simmen-Meuli; Ernst Reichmann; Martin Meuli Journal: Pediatr Surg Int Date: 2016-12-20 Impact factor: 1.827
Authors: Agnieszka S Klar; Sophie Böttcher-Haberzeth; Thomas Biedermann; Katarzyna Michalak; Marta Kisiel; Ernst Reichmann; Martin Meuli Journal: Pediatr Surg Int Date: 2014-10-18 Impact factor: 1.827